Skip to content

Multiple Sclerosis and Progressive Resistance Training

Multiple Sclerosis - Inflammatory, Neurological and Muscular Adaptations to Progressive Resistance Training

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01518660
Enrollment
35
Registered
2012-01-26
Start date
2012-02-29
Completion date
2014-01-31
Last updated
2014-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis (Relapsing Remitting)

Keywords

Resistance Training, Strength Training

Brief summary

The purpose of this study is to investigate underlying mechanisms possibly explaining the beneficial effects of progressive resistance training for people with multiple sclerosis.

Detailed description

Exercise in general, and progressive resistance training (PRT) in particular, is regarded as an important tool in the rehabilitation of people with multiple sclerosis (MS). Previous studies have reported positive effects of PRT on muscle strength, functional capacity, fatigue and quality of life. Also, a possible disease modifying effect has been proposed. However, the underlying physiological mechanisms that might explain these beneficial effects and the possible effects on disease progression are unresolved. Additionally, none of the previous studies has been concerned with the possible impact of MS progression type, gender and/or medication. The purpose of this randomized, controlled, gender stratified trial is to investigate underlying mechanisms possibly explaining the beneficial effects of progressive resistance training for people with multiple sclerosis.

Interventions

BEHAVIORALTraining

Bi-weekly progressive resistance training

Sponsors

Aarhus University Hospital
CollaboratorOTHER
Biogen
CollaboratorINDUSTRY
University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed relapsing-remitting MS according to the McDonald criteria * Expanded Disability Status Scale (EDSS) between 2.0 and 5.5 * Be able to train twice a week at the University * Use interferon based medication

Exclusion criteria

* Alcohol abuse, Alzheimer's and pacemaker (or other metallic implant) * Comorbidities like cardiovascular-, respiratory-, orthopaedic or metabolic diseases * Having had an attack in a period of 8 weeks prior to the start of the intervention period * Having an attack during the intervention period * Pregnancy * Systematic resistance training in a period of 3 months prior to the start of the intervention period. * Training adherence of less than 85%.

Design outcomes

Primary

MeasureTime frameDescription
Blood-borne biomarkersChange from baseline to 24 weeksResting levels of bloodbourne biomarkers; * Cytokines * Neurotrophins

Secondary

MeasureTime frameDescription
Walking performanceChange from baseline to 24 weeksWalking performance will be assessed by the; * Two minute walk test * 25-foot walk test * Chair rise test * Stair climb test
Self-reported measuresChange from baseline to 24 weeksThe self-reported measures contains questionnaires regarding; * Fatigue (Fatigue Severity Scale, Modifies Fatigue Impact Scale) * Health-Related Quality of Life (SF-36) * Depression (Major Depression Inventory) * Disease impact (MS Impact Scale 29) * Walking Performance (MS Walking Scale 12)
Neuro-muscular function of knee extensorsChange from baseline to 24 weeksBy use of an isokinetic dynamometer, EMG and stimulation equipment the following will be assessed for the knee extensors; * Maximal muscle strength * Surface EMG * Central activation ratio
Body CompositionChange from baseline to 24 weeksWeight and Bodyfat-% will be assessed with a Bodycomposition weight (Tanita SC220)
Thigh muscle cross-sectional areaChange from baseline to 24 weeksMRI-scans of the thigh will provide cross-sectional area of * m. quadriceps * m. hamstring
Brain volumeChange from baseline to 24 weeksMRI-scans of the head will provide the following measurements; * Brain volume (analysed with SIENA) * Plaque incidence

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026